As part of Emory School of Medicine’s commitment to advance bio innovation and entrepreneurship, Lab2Launch is designed to provide capital-efficient access to flexible coworking and wet laboratory space to Emory-affiliated companies developing promising technologies that ultimately improve patient health.

If you are a founder looking for wet lab space, please apply at https://bit.ly/lab2launchapp.

If you have any questions about the application process and Lab2Launch, visit our website.  in general, feel free to reach out to

For a quick reference of our offerings, please view/download our brochure.

Congratulations to David Weiss, PhD, co-PI of the Heteroresistance AST team, currently participating in the Biolocity Launch program. David Weiss, is the director of Emory’s Antibiotic Resistance Center and his team received a five-year $11 million grant from NIAID to continue their work in studying heteroresistance to treat bacterial infections.

Read More Here

Congratulations to Biolocity graduate company, Sanquina, on their newly announced collaboration with AstraZeneca on a study to develop a custom version of AnemoCheck Mobile, a smartphone application that provides noninvasive and equipment-free hemoglobin levels for patients with anemia of chronic kidney disease. Learn more about the collaboration here.

The AnemoCheck/Sanguina Team, Dr. Wilbur Lam and Erika Tyburski, received support from the Biolocity program (then the Coulter Translational Program) in 2016.  We are excited for their continued success and this new collaboration with AstraZeneca!

“Biolocity enabled us to receive an FDA 510(k) clearance on our first generation product. We couldn’t have done it without the support of Biolocity.”

– Erika Tyburski, AnemoCheck